Paris, 14 December 2016
Prescrire urges the French Health Products Agency (ANSM) to revise its draft recommendations on drug brand names in a way that maximises patient safety, abandoning national practices of brand names and labelling consisting of a hotchpotch of terms that cause medication errors by creating confusion. The ANSM is also urged to stop legitimising the continued presence of umbrella brands on the market, given the dangers they pose for patients, by challenging their regulatory compliance.
> Click here to download Prescrire's response (pdf, 226 Ko)
©Prescrire December 2016